Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Realm Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference


MALVERN, Pa., Feb. 20, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the RBC Capital Markets 2018 Global Healthcare Conference, on Thursday, February 22, 2018 at 8:00 a.m. ET at the Lotte New York Palace.

A live and archived webcast of the RBC presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation is available on the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in additional Ophthalmology and Dermatology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visit www.realmtx.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions.  Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

 

SOURCE Realm Therapeutics


These press releases may also interest you

at 10:00
Think On, Inc., a leading channel-only Canadian cloud solution provider with a global footprint, has entered into a distribution agreement with Arrow Electronics, a FORTUNE 109 value-added distributor. Arrow aggregates the world's leading...

at 09:59
FastWave Medical, a pre-revenue medical device company developing advanced intravascular lithotripsy (IVL) technology, proudly announces the issuance of its fourth utility patent by the United States Patent and Trademark Office (USPTO). This...

at 09:57
For the second year in a row, Info-Tech Research Group has been named to the 2024 LinkedIn Top Companies List in Canada. Ranking 15th on the list of 25 top...

at 09:53
Playtika, a mobile game powerhouse behind the World Series of Poker free-to-play app (WSOP), is calling on all poker aficionados to make a difference this National Poker Day. During a thrilling 72-hour Pokerthon, WSOP will be donating to DAV...

at 09:53
QA Systems, leading provider of software testing and verification tools, has announced the launch of Cantata Hybrid, a specialized software testing solution that allows organizations to generate certified test results and code coverage metrics from...

at 09:50
PharmAlliance, a diversified pharmaceutical and life sciences services platform, is pleased to announce the acquisition of Complete Health Economics Outcomes Research Solutions?CHEORS?a leading provider of health economics and outcomes research...



News published on and distributed by: